Michael Schweizer, MD: EZH2 Inhibitor Plus Enzalutamide in mCRPC

February 24, 2025 By The ASCO Post Staff

Michael Schweizer, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses findings from a randomized dose-expansion study of the investigational EZH2 inhibitor mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (Abstract LBA138).

Related Content